<table>
<thead>
<tr>
<th>Treatment Groups (mg/kg)</th>
<th>5 IV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Plasma</td>
</tr>
<tr>
<td>t_{1/2} (hour)</td>
<td>0.528 ± 0.105</td>
</tr>
<tr>
<td>Cl (L/hr*kg)</td>
<td>0.65 ± 0.08</td>
</tr>
<tr>
<td>V_{1} (L/kg)</td>
<td>0.48 ± 0.099</td>
</tr>
<tr>
<td>MRT (hour)</td>
<td>0.35 ± 0.02</td>
</tr>
<tr>
<td>AUC_{inf} (uM*hr)</td>
<td>20.32 ± 2.78</td>
</tr>
</tbody>
</table>
Toxicokinetics Data Summary

Experiment Number: S0312
Route: IV
Species/Strain: Rat/Fischer 344

Test Compound: Salicylazosulfapyridine
CAS Number: 599-79-1

Date Report Requested: 01/20/2017
Time Report Requested: 12:48:41
Lab: University of Arizona

LEGEND

Data are displayed as mean ± SEM

MODELING METHOD & BEST FIT MODEL
Unknown. Data were computed from the plasma concentration-time curves where each point represents the mean of 4 mice; first-order kinetics, Following iv injection, plasma clearance of SASP was consistent with a two compartment model

ANALYTE
Salicylazosulfapyridine

TK PARAMETERS

$t_{1/2} =$ Lambda, half-life, $t_{1/2}$, the terminal elimination half-life based on non-compartmental analysis
$Cl =$ Clearance, includes total clearance
$V_1 =$ Volume of distribution of the central compartment, includes $V_d$ and $V_{volume}$ of distribution, $V_z$ apparent volume of distribution NCA, $V_{app}$ apparent volume of distribution for intravenous studies
$MRT =$ Mean residence time
$AUC_{inf} =$ Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

** END OF REPORT **